MedTrace Logo

Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement

NCT02462837 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-06-13

Study results available
· View outcomes & findings →

Summary

The objective of this pilot study is to assess whether Myrbetriq™ will improve post-operative ureteral pain and discomfort, reduce bladder storage symptoms and increase quality of life following ureteral stenting.

Conditions

  • Urinary Bladder, Overactive
  • Pain
  • Lower Urinary Tract Symptoms

Interventions

DRUG

Mirabegron

DRUG

Placebo

Sponsors & Collaborators

  • Astellas Scientific & Medical Affairs, Inc.

    collaborator INDUSTRY

  • Sisters of the Third Order of St. Francis

    collaborator OTHER

  • Southern Illinois University

    lead OTHER

Principal Investigators

  • Ahmed El-Zawahry, MD · SIUSOM - Division of Urology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2019-01-30
Completion
2019-01-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462837 on ClinicalTrials.gov